Brigham Young University revealed on Thursday that its FDA listed alcohol-free Disinfect & Shield hand sanitizer containing benzalkonium chloride are just as effective against the COVID-19 virus as alcohol-based products based on a new research based study.
The new study was reportedly published in The Journal of Hospital Infection.
According to the university , the Disinfect & Shield Hand Sanitizer is available as a moisture-infused foam or spray that leaves an invisible, breathable barrier on the skin. It not only destroys 99.99% of bacteria but is also eco-friendly, making it ultra-safe for use around pets and plants while protecting the treated area for up to a full eight hours. The product is effective against numerous viruses, bacteria, moulds, and fungi enveloped and non- enveloped, including strains of SARS, MRSA and Staph infection.
Disinfect & Shield is a fast-acting nanotechnology that destroys viruses and bacteria and prevents them from attaching to skin, surfaces, and clothes. The colourless, odourless, positively charged polymer bonds to the treated surface creating a layer of electrically charged swords. They protect the surface from biofilm growth by puncturing the cell membrane. It is alcohol-free and eliminates the harsh fumes and cracked, dry skin that accompanies alcohol-based sanitizers and its safe for use on PPE like gloves, concluded the university.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA